Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan
Jun‐ichi Nishimura, Tatsuya Kawaguchi, Shuichi Ito, Hiroyuki Murai, Akihiko Shimono, Takahisa Matsuda, Yuji Fukamizu, H Akiyama, Hideo Hayashi, Takashi Nakano, Shoichi Maruyama
Topics & Concepts
EculizumabParoxysmal nocturnal hemoglobinuriaMedicineInternal medicineIncidence (geometry)HemoglobinuriaPneumoniaAtypical hemolytic uremic syndromeAdverse effectSepsisMyasthenia gravisHematologyPediatricsGastroenterologyAnemiaImmunologyAntibodyComplement systemPhysicsOpticsComplement system in diseasesCoagulation, Bradykinin, Polyphosphates, and AngioedemaRenal Diseases and Glomerulopathies